Format

Send to

Choose Destination
Drug Discov Today. 2015 Oct;20(10):1228-34. doi: 10.1016/j.drudis.2015.06.003. Epub 2015 Jun 19.

Targeting the podocyte to treat glomerular kidney disease.

Author information

1
CVMD iMED, AstraZeneca, Mölndal, Sweden. Electronic address: mark.lal@astrazeneca.com.
2
Evotec AG, Germany.

Abstract

The majority of chronic kidney disease (CKD) cases have their origin in the glomerulus, the microvascular unit of the nephron that serves as a filter tasked with forming primary urine. This selective filtration process is determined to a large extent by the functional capacity of the podocyte, a highly differentiated cell type that enwraps the outer aspect of the glomerular capillary wall. In this short review, we describe the biology of the podocyte, its central role in the etiology of various glomerulopathies and highlight current and future opportunities to exploit the unique properties of this cell type for developing kidney-specific therapeutics.

PMID:
26096184
DOI:
10.1016/j.drudis.2015.06.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center